mots-c

mots-c (also known as MOTS-c or Mitochondrial ORF of the 12S rRNA type-c) is a therapeutically researched peptide studied for its effects on metabolic health, fat loss, anti-aging. 16-amino-acid mitochondrial-derived peptide that activates AMPK and translocates to the nucleus to regulate metabolism. In rodents it improves insulin sensitivity and mimics exercise adaptations, and circulating levels fall with age. Investigational 'exercise-mimetic' peptide; human efficacy is unproven and evidence is preclinical.

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial genome rather than the nuclear DNA. It functions as a regulator of metabolic homeostasis: under metabolic stress such as glucose restriction or exercise, MOTS-c translocates from the cytoplasm to the nucleus, where it helps direct an adaptive antioxidant and metabolic stress response, in part through activation of AMP-activated protein kinase (AMPK). In cell and rodent models it enhances glucose uptake and insulin sensitivity, improves lipid metabolism, reduces diet-induced obesity, and reproduces and amplifies several of the metabolic adaptations normally produced by physical exercise, leading some researchers to describe it as an 'exercise-mimetic' peptide.

Overview

Circulating MOTS-c levels decline with age and are altered in metabolic disease.

MOTS-c is an investigational research peptide with no approved human indication.

Human data are largely limited to observational associations between endogenous MOTS-c levels and fitness or metabolic status; demonstrated efficacy comes from preclinical cell and animal experiments, not controlled human trials.

Mechanism of action

Mitochondrial-derived peptide that activates AMPK to improve insulin sensitivity and reproduce exercise-like metabolic adaptations in preclinical models. Investigational; no approved human use and unproven human efficacy.

Reported effects

Effects reported in the literature and from preclinical models include:

• MOTS-c improves insulin sensitivity and glucose uptake in skeletal muscle in preclinical models, including a gestational diabetes mouse model. ^[2] Preclinical
• Systemic MOTS-c administration increases exercise performance and metabolic adaptation to exercise in animal models. ^[3] Preclinical
• MOTS-c stimulates thermogenesis in subcutaneous white adipose tissue, enhancing energy expenditure and contributing to anti-obesity effects in preclinical models. ^[3] Preclinical
• Under metabolic stress, MOTS-c translocates to the nucleus to regulate antioxidant response genes via AMPK and NRF2 in cell models. ^[1] Preclinical
• Exogenous MOTS-c attenuates lung injury and modulates inflammation and oxidative stress in preclinical respiratory disease models. ^[4] Preclinical
• MOTS-c administration in a gestational diabetes mouse model reduced hyperglycemia, improved glucose tolerance, and decreased adverse offspring outcomes including neonatal death. ^[2] Preclinical

Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal

Dosage and administration

General

• Investigational research peptide with no established or approved human dose
• Rodent studies use intraperitoneal dosing in the 0.5-15 mg/kg range
• Human interventional dosing has not been validated in controlled trials

Natty status

mots-c is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.^[5]

Research

The peptide has been the subject of 5 studies and reference works collected on this site. The full bibliography is in § External links below.

Related compounds

Other peptides in this catalogue with overlapping mechanisms or status:

References

1. ^ The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Metabolic Homeostasis (Cell Metab 2018)
2. ^ a b MOTS-c relieves hyperglycemia and insulin resistance (preclinical, Pharmacol Res 2022)
3. ^ a b Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c) (review, Diabetes Metab J 2022) Recent
4. ^ MOTS-c: How a secreted mitochondrial microprotein may become a potential treatment for inflammatory lung diseases. Recent review
5. ^ a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.